首页> 外文期刊>Central European Journal of Urology: The Polish Journal of Urology >The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors
【24h】

The new horizons of pharmacotherapy. Unexpected pharmacological actions and a new therapeutic strategy of phosphodiesterase–5 inhibitors

机译:药物治疗的新视野。磷酸二酯酶-5抑制剂的意外药理作用和新治疗策略

获取原文
获取外文期刊封面目录资料

摘要

Introduction Benign prostate hyperplasia and erectile dysfunction affect a significant subset of men.BPH and ED may have the same promoting conditions and are the strong predicting risk factors to eachother. A significant number of these patients are bothered by lower urinary tract symptoms (LUTS). Directcorrelation of age, sexual dysfunction and LUTS severity has been well documented. Many sexuallydysfunctional patients with concomitant BPH receive alpha–adrenergic antagonists and any Phosphodiesterase–5 (PDE5) inhibitor simultaneously. PDE5 inhibitors relieve LUTS symptoms in the course of BPHand reduce independent detrusor contractions. This paper presents the results of clinical trials on theefficacy of PDE5 inhibitors on LUTS, new perspectives on its use and newly–identified side effects.Material and methods The review is based on an internet search of PubMed and Medscape databases.The search terms were as follows: LUTS and ED, BPH and phosphodiesterase–5 inhibitors, LUTSclinical trials, phosphodiesterase–5 inhibitors mechanisms.Results Clinical trials show an epidemiological and pathophysiological relationship between BPH, LUTSand ED. Numerous studies reveal the alleviating effect of phosphodiesterase–5 inhibitors on LUTS, expressedas the reduction of IPSS score, but not followed by a change in Qmax. Opponents raise a link ofPDE5 inhibitors with increased risk of melanoma. New studies reveal that phosphodiesterase–5 inhibitorsare effective in the treatment of neurological disorders.Conclusions Researches reveal the efficacy of phosphodiesterase–5 inhibitors in LUTS along with animprovement of erectile function. The molecular mechanism of action of such drugs suggests imminentnovel applications. Potential benefits will be multidimensional. Unfortunately, interfering with particularmolecular mechanisms may alleviate some diseases, but may lay groundwork for others – new and evenmore devastating.
机译:前言良性前列腺增生和勃起功能障碍会影响大量男性。BPH和ED可能具有相同的促进条件,并且是相互强烈的预测危险因素。这些患者中有相当多的患者受到下尿路症状(LUTS)的困扰。年龄,性功能障碍和LUTS严重程度的直接相关性已得到充分证明。许多伴有BPH的性功能障碍患者同时接受α-肾上腺素能拮抗剂和任何磷酸二酯酶-5(PDE5)抑制剂。 PDE5抑制剂可在BPHand过程中缓解LUTS症状,减少独立的逼尿肌收缩。本文介绍了PDE5抑制剂对LUTS有效性的临床试验结果,其使用的新观点以及新近发现的副作用。材料和方法综述基于PubMed和Medscape数据库的互联网搜索。如下:LUTS和ED,BPH和磷酸二酯酶5抑制剂,LUTS临床试验,磷酸二酯酶5抑制剂的作用机制。结果临床试验表明BPH,LUTS和ED之间存在流行病学和病理生理学关系。大量研究揭示了磷酸二酯酶-5抑制剂对LUTS的缓解作用,表现为IPSS评分的降低,但并未随Qmax的改变而变化。反对者提出PDE5抑制剂与黑色素瘤风险增加之间的联系。新的研究表明,磷酸二酯酶-5抑制剂可有效治疗神经系统疾病。结论研究表明,磷酸二酯酶-5抑制剂在LUTS中的疗效与勃起功能的改善有关。这类药物的分子作用机理表明即将出现新的应用。潜在的好处将是多维的。不幸的是,干扰特定的分子机制可能减轻某些疾病,但可能为其他疾病打下基础,这是新的甚至是毁灭性的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号